TapImmune reports positive interim safety analysis in breast cancer study
Vaccine technologies company TapImmune has reported that positive interim safety analysis was achieved in breast cancer patients treated with HER2/neu antigens.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | HER2 | Pharmaceuticals | Study | Vaccines